antibacterial agent 34

Antibacterial agent 35 is a compound that effectively reduces the minimum inhibitory concentration (MIC) of Ceftazidime, enhancing its antibacterial activity.

4-(4,5-dibromo-6-oxo-1,6-dihydropyridazin-1-yl)benzene-1-sulfonamide is a sulfonamide derivative used in the synthesis of building blocks for various supramolecular structures such as metal-organic skeletons and coordination polymers. It has antiproliferative activity against a variety of tumor cell lines.

Antibacterial agent 132 showed antimicrobial activity against C. parapsilosis (ATCC 22019) and C. krusei (ATCC 6258) with MIC90 values of <0.06 μg/mL and 62.50 μg/mL, respectively. Antibacterial agent 132 inhibited aromatase enzyme with IC50 of 0.047 μM.

(2S)-4-biphenyl-4-yl-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide is a LpxC inhibitor with IC50 >95.2 nM.

Antiviral agent 34 is an orally available, potent antiviral compound that inhibits influenza A and B viruses.Antiviral agent 34 inhibits the proliferation of influenza viruses by modulating RNA polymerase.Antiviral agent 34 is used in the study of viral infections.

Antibacterial agent 162 trifluoromethanesulfonate (compound 7), a dual-function molecule, demonstrates potent inhibitory effects on Staphylococcus aureus, encompassing MRSA strains, and exerts antiproliferative activity against colon cancer and non-small cell lung cancer cells. This compound is applicable in both anticancer and antibacterial research [1].

Compound 6 (Antibacterial agent 161, trifluoromethanesulfonate) exhibits antibacterial properties and demonstrates significant antiproliferative effects against colon cancer and non-small cell lung cancer [1].

Antibacterial Agent 160 is a potent antibacterial agent that rapidly eradicates bacteria and inhibits the formation of bacterial biofilms. It disrupts the normal functioning of DNA, resulting in cellular death [1].

Antibacterial agent 165 (compound 3), a hydroxyquinoline derivative, effectively inhibits methicillin-resistant Staphylococcus aureus (MRSA) [1], demonstrating its potent antibacterial properties.

Anti-inflammatory agent 34 shows moderate acute anti-inflammatory activity and analgesic activity in vivo.

Antibacterial agent 163 (compound 1), a hydroxyquinoline derivative, potently inhibits methicillin-resistant Staphylococcus aureus (MRSA) [1].

Antibacterial agent 66 (Compound 6q) is a trifluoromethylpyridine 1,3,4-oxadiazole derivative active against Xanthomonas oryzae pv. oryzae (Xoo) (EC50: 7.2 μg/mL).

Antibacterial agent 37 is an effective antimicrobial compound. It holds potential as a valuable tool for researching bacterial infections.

Antibacterial Agent 42 demonstrates potent antibacterial activity by effectively reducing the Minimum Inhibitory Concentration (MIC) of the broad-spectrum antibacterial agent Ceftazidime.

Antibacterial agent 30 exhibits remarkable in vitro activity against Xoo, as evidenced by its EC50 value of 1.9 μg/mL.

Antibacterial agent 57 (example 25) is a antibacterial agent.

Antibacterial agent 88 is an effective antibacterial agent against B. subtilis (MIC: 4 μg/ml) with MIC values of ≤0.0156 μg/mL for MRSA, MRSE and S. aureus.

Antibacterial agent 131 is a compound with antibacterial properties.

Antibacterial agent 92, a triple-site aminoacyl-tRNA synthetase (aaRS) inhibitor, demonstrates a potent antibacterial effect by inhibiting Salmonella enterica threonyl-tRNA synthetase (SeThrRS) with an IC50 of 0.58 μM.

Aztreonam-siderophore conjugate 63 is an antibacterial agent that exhibits efficacy against Gram-negative bacteria through the linkage of aztreonam to a siderophore mimetic.

Compound A11 (Antibacterial agent 86) exhibits the highest bacteriostatic activity against methicillin-resistant S. aureus, with minimum inhibitory concentration (MIC) values reaching as low as 0.00191 μg/mL. This efficacy is 162 and 32 times greater than the commercial antibiotics tiamulin and retapamulin, respectively [1].

Antibacterial Agent 136 (Compound 3), an oxadiazolone antibiotic, exhibits high antibacterial potency against Methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration (MIC) 50 value of 0.8 μM [1].

Antibacterial agent 116, a benzophenone-containing salicylanilide compound, exhibits potent antibacterial activity by inhibiting peptidoglycan formation. It is employed as a photoaffinity probe to label Acinetobacter baumannii penicillin-binding protein (PBP1b), thereby blocking the propagation pathway and disrupting the growth of the peptidoglycan chain.

Antibacterial Agent 128, a siderophore analog-Ciprofloxacin (Ciprofloxacin) conjugate connected via a cleavable linker, demonstrates effective antibiotic properties. Specifically, it exhibits activity against P. aeruginosa and B. pseudomallei, with Minimum Inhibitory Concentration (MIC) values ranging from 0.25 to 64 μg/mL and 1 to 32 μg/mL, respectively [1].

Antibacterial Agent 123 (Compound 111) serves as an effective membrane-disrupting agent targeting antibiotic-resistant Gram-positive bacteria [1].

Antibacterial agent 75 (compound 24) possesses antibacterial properties. Its notable attribute is the ability to re-sensitize VRSA (Vancomycin-Resistant Staphylococcus aureus) strains to vancomycin, as reported in reference [1].

Antibacterial agent 46, serves as a potent antibacterial compound. With its versatile properties, this agent demonstrates considerable potential for supporting research on bacterial infections.

Antibacterial agent 101 exhibited antibacterial and antifungal effects (MIC=4-32 μg/mL).

Antibacterial agent 98 (compound g37) is an effective oral antibacterial agent, which can inhibit the ATPase activity of Gyrase B and weaken the DNA super-helix of S. aureus. Antibacterial agent 98 does not induce the development of MRSA (methicillin-resistant Staphylococcus aureus) resistance.

Antibacterial Agent 33, a potent antibacterial compound, effectively decreases the minimum inhibitory concentration (MIC) of Ceftazidime, another antibacterial agent.

Antibacterial agent 80 (compound 20) has antibacterial activity [1].

Antibacterial agent 32 exhibits potent antimicrobial activity against E. coli strains NCTC 13351, M 50, and 7 MP, with minimum inhibitory concentration (MIC) values of 1 mcg/mL, 2 mcg/mL, and 8 mcg/mL, respectively (WO2013030733A1, example 43).

Antibacterial agent 62 is a novel redox cycle anti-tuberculosis compound that exhibits significant bactericidal activity against growth and nutrient deficient phenotypically resistant non-growing bacteria.

Antibacterial agent 55 (example 21) is a antibacterial agent.

Antibacterial agent 48 is an antimicrobial agent that reduces the MIC of the antimicrobial agent Ceftazidime.

Antibacterial agent 94 (compound 5b) is a highly effective antibacterial agent that demonstrates strong activity against various bacterial strains. Notably, Antibacterial Agent 94 is capable of eradicating MRSA persisters, highlighting its potential as a therapeutic solution. Its mechanism of action involves interference with the bacterial membrane and disruption of the phosphatidylglycerol (PG) synthesis pathway [1].

Anticancer agent 34 (compound 9) is a sulfonylurea derivative and a potent anti-microbial and anti-cancer agent. anticancer agent 34 showed inhibition of microbial growth of Mycobacterium, Escherichia coli and Candida albicans (MIC: 0.039-0.156 mg/ml). Anticancer agent 34 inhibited the growth of A549 cells (IC50: 8.4 μg/ml), PC3 cells (IC50: 7.8 μg/ml).

Antibacterial agent 27 has potent anti-Candida activity.

Antibacterial Agent 156 (Compound 57), a bactericidal that selectively targets C. difficile cell-wall synthesis, demonstrates potent activity with minimal inhibitory concentrations of 0.5 μg/mL for MIMIC50 (101 strains) and 1 μg/mL for MIC90 (101 strains) [1].

Antibacterial agent 153 is a broad-spectrum agent that eradicates bacteria by targeting their cell membranes and is employed in research on bacterial infections [1].

Compound 6d (Antibacterial agent 159) is an antibiotic effective against impetigo and Clostridium difficile infection (CDI), with no observed recurrence for CDI and minimal impact on the beneficial gut microbiome [1].

Antibacterial agent 73 (compound 7a) exhibits antitubercular, antibacterial, and antifungal activities. Antibacterial agent 73 exhibits promising antitubercular activity with MIC of 0.65 μg/mL against Mtb H37Rv. Antibacterial agent 73 also exhibits cytotoxicity in MCF-7 breast cancer cell lines with IC 50 of 8.20 μM [1].

Antibacterial agent 90 (6n) is an antibacterial pleuromutilin derivative that exhibits antibacterial activity against Gram-positive pathogens (GPPs) and Mycoplasma pneumoniae.

Antibacterial agent 59 (example 24) is a antibacterial agent.

Antibacterial Agent 58 (AA58) is a potent antibacterial compound that effectively reduces the minimum inhibitory concentration (MIC) value of Ceftazidime, another antibacterial agent.

Antibacterial agent 18, a multi-arm AIE molecule, demonstrates efficacy against both Gram-positive and Gram-negative bacteria. Antibacterial agent 18 functions by conjugating with the cell wall of bacteria with rigid arm configuration, thereby interfering with the sugar and peptide processes essential for cell wall turning. This mechanism inhibits or eradicates bacterial growth[1].

Antibacterial Agent 47 demonstrates potent antibacterial activity as an adjunct therapy to parenteral antibiotic Ceftazidime. By effectively reducing the minimum inhibitory concentration (MIC) of Ceftazidime, Antibacterial Agent 47 acts as a highly promising antimicrobial agent, thereby enhancing the overall efficacy of the treatment.

Antibacterial agent 60 is a potent compound that effectively reduces the minimum inhibitory concentration (MIC) of Ceftazidime, an antibacterial agent.

Antibacterial agent 49 (example 12) is a antibacterial agent.

Antibacterial agent 100 (Compound 7c) is an antibacterial and fungal agent that acts on Staphylococcus aureus (MIC: 4 μg/mL), Candida albicans (MIC: 4 μg/mL) and Cryptococcus neoformans (MIC: 4 μg/mL). neoformans (MIC: 8 μg/mL).